25 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/25/3049233/0/en/Theratechnologies-Receives-FDA-Approval-for-EGRIFTA-WR-Tesamorelin-F8-to-Treat-Excess-Visceral-Abdominal-Fat-in-Adults-with-HIV-and-Lipodystrophy.html
13 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/14/3026381/0/en/Theratechnologies-Resumes-Distribution-of-EGRIFTA-SV.html
09 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/09/3007379/0/en/Theratechnologies-Provides-Update-on-EGRIFTA-SV-Supply.html
10 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/10/2994926/0/en/Theratechnologies-Receives-March-2025-PDUFA-Goal-Date-for-Updated-Tesamorelin-F8-Formulation-sBLA.html
26 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/26/2987389/0/en/Theratechnologies-Submits-Updated-Tesamorelin-F8-Formulation-sBLA-for-FDA-Review.html
18 Sep 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/theratechnologies-warns-hiv-med-disruption-after-third-party-plant-shutdown